论文部分内容阅读
目的：观察吉西他滨联合厄洛替尼治疗晚期胰腺癌的临床效果，为晚期胰腺癌的二线治疗方案提供依据。方法112例晚期胰腺癌患者随机分为试验组和对照组，各56例。对照组静脉滴注吉西他滨1000 mg · m－2，滴注时间为30 min，每周1次，21 d为1个周期，至少进行2个周期的化疗；试验组在对照组的基础上第1，8天口服厄洛替尼100～150 mg· d－1，21 d为1个周期。每2个周期评定一次临床疗效，包括临床总有效率，临床受益反应和不良反应发生情况。结果试验组临床总有效率为66.1％，显著高于对照组的39.3％（ P＜0.05）。试验组临床受益率为71.4％，显著高于对照组的44.6％（ P＜0.05）。试验组患者骨髓抑制及胃肠道反应的发生率与对照组差异无统计学意义（ P＞0.05）。结论吉西他滨联合厄洛替尼治疗晚期胰腺癌临床效果显著，可以明显的提高临床总有效率及临床受益率，且不增加不良反应。“,”Objective To investigate the clinical effect of gemcitabine combined with erlotinib in the treatment of advanced pancreatic cancer, and provide more information for the second-line treatment of this dis-ease.Methods A total of 112 patients of advanced pancreatic cancer were randomly divided into treatment group and control group, 56 cases in each group.Patients in control group were given monotherapy of gem-citabine 1000 mg· m-2 for 30 min, one dose in a week, and 3 weeks a cycle, and treated at least 2 cycles.Patients in treatment group were treated with gemcitabine and erlotinib.The dosing plan of gemcitabine was just as control group, and on day 1 and 8 in every cycle the patients were given the treatment of erlotinib 100-150 mg· d-1 , 21 d a cycle, and treated at least 2 cycles.The clinical effects including total clinical effective rate, the clinical benefit effect and the adverse drug reactions were evaluated.Results The total clinical effective rate of treatment group was 66.1%, which was significantly higher than that of control group of 39.3% ( P<0.05 ).The clinical benefit rate was 71.4% in treatment group and 44.6%in control group, with statistically significant difference ( P0.05).Conclusion It had significant clinical effec t of gemcitabinecombined with erlotinib in the treatment of advanced pancreatic cancer, the total clinical effect rate and clinical benefit rate were improved significantly, but without more adverse reactions.